Area of research
Endocrinology, Diabetes and Metabolism · Cardiology and Cardiovascular Medicine
Research interest
Originally from Fayetteville, Arkansas, Dr. McGuire holds a bachelor’s degree in chemistry from Hendrix College in Conway. He earned his medical degree at the Johns Hopkins University School of Medicine in Baltimore and completed internal medicine residency training at UT Southwestern. He then received advanced training in cardiology through a fellowship at Duke University in Durham, North Carolina, where he also conducted research for two years, working on a number of large-scale, international clinical trials and registries at the Duke Clinical Research Institute (DCRI). He also earned a master’s degree in health sciences in clinical trials at the Duke University School of Medicine.
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria
Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials
Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction
PREVENT Equations: A New Era in Cardiovascular Disease Risk Assessment
Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure
Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations
Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases
Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials
Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events
Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial
Leveraging electronic health records to streamline the conduct of cardiovascular clinical trials
Natriuretic Peptides, Body Mass Index and Heart Failure Risk: Pooled Analyses of SAVOR-TIMI 53, DECLARE-TIMI 58 and CAMELLIA-TIMI 61
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials
UCL Discovery (University College London) 2022cited by 213position: middle
Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus
Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58
Comparison of Accuracy of Estimation of Cardiac Output by Thermodilution Versus the Fick Method Using Measured Oxygen Uptake
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial
Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial
Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58
Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes
Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial
Biomarker-Based Risk Prediction of Incident Heart Failure in Pre-Diabetes and Diabetes
The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58